A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours

BACKGROUND: Combined focal adhesion kinase (FAK) and MEK inhibition may provide greater anticancer effect than FAK monotherapy. METHODS: This dose-finding phase Ib study (adaptive 3 + 3 design) determined the maximum tolerated dose (MTD) of trametinib and the FAK inhibitor GSK2256098 in combination....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Mak, Gabriel, Soria, Jean-Charles, Blagden, Sarah P., Plummer, Ruth, Fleming, Ronald A., Nebot, Noelia, Zhang, Jianping, Mazumdar, Jolly, Rogan, Debra, Gazzah, Anas, Rizzuto, Ivana, Greystoke, Alastair, Yan, Li, Tolson, Jerry, Auger, Kurt R., Arkenau, Hendrik-Tobias
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6735221/
https://ncbi.nlm.nih.gov/pubmed/30992546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0452-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados